CERO · Cero Therapeutics Holdings, Inc.
$0.01
+0.00 (+0.00%)
At close · Jul 30
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these unaudited condensed consolidated financial statements are issued.”View the 10-Q filed May 15, 2026
Market Cap
$451,124
Shares
45.11M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$19.92M
-157.6%
FY2025
Diluted EPS
-$363.00
+98.5%
FY2024
Operating Cash Flow
-$16.1M
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| — | — | $6.32M | $5.29M | — | — | |
| — | — | $8.99M | $2.39M | $2.84M | $251.71K | |
| — | — | $15.3M | $7.68M | $2.91M | $332.03K | |
| — | — | -$15.3M | -$7.68M | -$2.91M | — | |
| — | — | -$21.85K | -$138.34K | — | — | |
| — | — | — | $491.57K | $2.84M | — | |
| — | — | $7.57M | $385.47K | — | — | |
| — | -$19.92M | — | -$2.44M | -$68.58K | -$332.42K | |
| — | — | — | $94.82K | $599.16K | -$16.87K | |
| -$20.7M | -$19.92M | -$7.73M | -$7.29M | -$667.74K | -$315.55K | |
| — | — | -$10.52M | -$7.29M | -$21.41M | -$21.41M | |
| USD/shares | — | — | -$363.00 | -$24,972.80 | — | — |
| USD/shares | — | — | -$363.00 | -$24,972.80 | — | — |
| shares | — | — | 28.97K | 291.9 | — | — |
| shares | — | — | 28.97K | 291.9 | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2025: $172.84M in buybacks, $127.14K in dividends.